96th DOG Annual Meeting, 1998

V253

EARLY CLINICAL EXPERIENCES WITH MYCOPHENOLATE MOFITILE (CELLCEPT) IN IMMUNOSUPPRESSIVE THERAPY OF AUTOIMMUNE DISEASES OF THE EYE

J. Zurdel, B. Aboalchamat, K. Engelmann, A.A. Bialasiewicz

Autoimmune diseases or chronic inflammatory lesions of the eye can lead to severe damage or even loss of vision. Systemic immunosuppressive therapy with a single agent or with a combination of substances, namely of corticosteroids, ciclosporine A and azathioprine is often inevitable for a period of months or years, cyclophosphamide and methotrexate are being used less often. The side effects of these drugs are well known and limit their use. Even despite of immunosuppressive therapy sometimes the disease takes a chronically relapsing couse.

Methods: For 1 year patients who did not improve under standard single immunosuppressants or who required a combination of them were being treated with a dosage of 1 g of mycophenolate mofitile taken twice daily.

Results: Among the patient in this clinical trial were 3 patients with ocular pemphigoid, 6 patients with re-keratoplasty or recurrent transplant rejection and 2 patients with retinal vasculitis. Due to this treatment 3 patients did no longer depend on longterm corticosteroids, in 1 patient imminent loss of sight was prevented. Other cases will be presented.

Discussion: The new substance mycophenoate mofitile - as a monotherapy or in combination with other immunosuppressants - might be able to control severe conditions of autoaggressive diseases. These results should warrant longterm investigation.

Universit├Ąts-Augenklinik, Martinistr. 52, D-20246 Hamburg


Back